Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
Thomas Powles(St Bartholomew's Hospital), Petros Grivas(Fred Hutch Cancer Center), Jeanny B. Aragon‐Ching(Inserm), Howard Gurney(Radboud University Nijmegen), Srikala S. Sridhar(Princess Margaret Cancer Centre), Bo Huang(Inserm), Begoña P. Valderrama(Inserm), Se Hoon Park(Samsung Medical Center), Claudia Caserta(Inserm), Joaquim Bellmunt(Radboud University Nijmegen), Anders Ullén(Inserm), Jing Wang(University of South China), Alessandra di Pietro(Inserm), Cora N. Sternberg(Radboud University Nijmegen), Robert J Laliberte(Inserm), Yohann Loriot(Université Paris-Sud)
Cited by 210
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k